Rucaparib: Metastatic Castration-Resistant Prostate Cancer

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

  • Clinical Trial Information

    Trial Contact: Walton, Sherri; Manchola-Orozco, Carolina

    Trial Phone: 321.841.1907 ; 321.841.7293

  • IRB No: 16.147.11

    Protocol Abbrev: TRITON 2

    Principal Investigator: Julio J. Hajdenberg, MD

    Phase: Drug: Phase II

    Age Group: Adult

    Secondary Protocol No: CO-338-052

    Treatment: Rucaparib tablets

    Therapies Involved: Medication ID: NCT02952534

  • Objective

    The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.

  • Key Eligibility

    Male ≥ 18 years of age Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate Surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL (1.73 nM)Evidence of disease progression after prior therapy for mCRPCMolecular evidence of mCRPC associated with HRD